logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Skin Disease, Burns and Wound Care

Results

Drugs

May 2020

Tralokinumab for adolescents with moderate to severe atopic dermatitis

Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein, interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is administered subcutaneously and is currently licenced for the treatment of adults. Evidence from clinical trials suggests an improvement in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adolescents with moderate to severe AD.

Drugs

February 2020

Abrocitinib for moderate to severe atopic dermatitis

Abrocitinib is a medicinal product taken by mouth (tablets) and acts by selectively blocking a protein called Janus Kinase 1 (JAK-1). JAKs contribute to cell processes that result in an immune or inflammatory response. JAK dependent enzymes are major contributors to the progression of immune-mediated diseases such as AD. Therefore, blocking these enzymes may be beneficial. Abrocitinib, if licensed, may offer the first oral, once-daily treatment option for patients with moderate to severe AD.

Drugs

November 2019

Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years

Secukinumab as a subcutaneous injection is in clinical development for the treatment of enthesitis related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). These conditions belong to a group of arthritis conditions of unknown cause known as juvenile idiopathic arthritis which affect children. JPsA patients have arthritis and psoriasis, an inflammatory skin disease and ERA patients have arthritis and enthesitis, inflammation of the ligaments and tendons. These conditions are the result of the immune system mistakenly attacking the body’s own cells at the joints and the skin or tendons, causing swelling, pain and reduced mobility.

Drugs

November 2019

Upadacitinib for atopic dermatitis

Upadacitinib is in development for the treatment of moderate to severe atopic dermatitis (AD). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin …

Drugs

November 2019

Tralokinumab for atopic dermatitis

Tralokinumab is in development for the treatment of moderate to severe atopic dermatitis (AD) uncontrolled with currently available therapies in adult patients who are candidates for systematic therapy. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.

Drugs

August 2019

Bimekizumab for moderate to severe chronic plaque psoriasis

Bimekizumab is in clinical development for moderate to severe chronic plaque psoriasis. Plaque psoriasis is a persistent, long lasting chronic inflammatory disease causing red, flaky and itchy patches of skin commonly appearing on the elbows, knees, scalp and lower back. Plaque psoriasis is an autoimmune disease, meaning that the immune cells which usually fight infection attack the body’s own tissues instead, in this case, the skin. Treatment is determined by the type and severity of psoriasis, and the area of skin affected, and may include a combination of topical, phototherapy and systemic (oral or injected) therapies.

Drugs

June 2019

Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis

Dupilumab is in development for the treatment of children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) uncontrolled with currently available therapies. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.

Drugs

May 2019

Secukinumab for moderate to severe plaque psoriasis in children aged 6 to less than 18 years old

Secukinumab is a monoclonal antibody, a type of protein, designed to recognise and attach to a messenger molecule in the immune system called interleukin 17A. This molecule is involved in the inflammation and other immune system processes that cause psoriasis. By attaching to and blocking the action of interleukin 17A, secukinumab reduces the activity of the immune system and the symptoms of the disease. If licensed, secukinumab will offer a first-line systemic treatment option in children and adolescents with moderate to severe plaque psoriasis in patients who are candidates for systemic therapy.

Drugs

March 2019

Baricitinib for moderate to severe atopic dermatitis

Baricitinib acts by selectively and reversibly blocking the janus-associated kinase (JAK) enzymes that mediate the pathways involved in the inflammatory process in AD and other inflammatory diseases. Baricitinib is taken orally and is currently licensed for the treatment of moderate to severe active rheumatoid arthritis in adult patients that have not responded well to other therapies. If licensed, baricitinib will offer an additional treatment option for adults with moderate to severe AD.

Drugs

June 2018

Oleogel-S10 for Inherited Epidermolysis Bullosa

Oleogel-S10 is a topical gel and is being developed as a prescription medicine as for EB, for which there are limited treatment options. Oleogel-S10 causes the keratinocytes (cells that regenerate the outer layer of the skin) to migrate (move across the wound) and become mature epithelial skin cells, resulting in rapid wound healing. If licensed, oleogel-S10 will offer a treatment option for wound care in patients with EB who currently have limited therapies available.

Get Alerts